Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia.

Jariyavilas A, Thavichachart N, Kongsakon R, Chantakarn S, Arunpongpaisal S, Chantarasak V, Jaroensook P, Kittiwattanagul K, Nerapusee O.

Neuropsychiatr Dis Treat. 2017 Jan 12;13:141-146. doi: 10.2147/NDT.S112063. eCollection 2017.

2.

Asenapine for the Control of Physical Aggression: A Prospective Naturalist Pilot Study.

Amon JS, Johnson SB, El-Mallakh RS.

Psychopharmacol Bull. 2017 Jan 26;47(1):27-32.

3.

Proximal Risk Factors for Short-Term Community Violence Among Adults With Mental Illnesses.

Johnson KL, Desmarais SL, Grimm KJ, Tueller SJ, Swartz MS, Van Dorn RA.

Psychiatr Serv. 2016 Jul 1;67(7):771-8. doi: 10.1176/appi.ps.201500259. Epub 2016 Feb 29.

4.

Current status of clozapine in the United States.

Kelly DL, Wehring HJ, Vyas G.

Shanghai Arch Psychiatry. 2012 Apr;24(2):110-3. doi: 10.3969/j.issn.1002-0829.2012.02.007. No abstract available.

5.

Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital.

Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, Vinestock M, Das M.

CNS Spectr. 2014 Oct;19(5):391-402. doi: 10.1017/S1092852914000157. Epub 2014 Apr 3.

6.

Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Volavka J, Czobor P, Citrome L, Van Dorn RA.

CNS Spectr. 2014 Oct;19(5):374-81. doi: 10.1017/S1092852913000849. Epub 2013 Nov 28. Erratum in: CNS Spectr. 2014 Oct;19(5):466.

7.

Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review.

[No authors listed]

CADTH Technol Overv. 2012;2(3):e2301. Epub 2012 Sep 1. No abstract available.

8.

Quantifying clinical relevance in the treatment of schizophrenia.

Correll CU, Kishimoto T, Nielsen J, Kane JM.

Clin Ther. 2011 Dec;33(12):B16-39. doi: 10.1016/j.clinthera.2011.11.016. Review.

9.

Pathways to aggression in schizophrenia affect results of treatment.

Volavka J, Citrome L.

Schizophr Bull. 2011 Sep;37(5):921-9. doi: 10.1093/schbul/sbr041. Epub 2011 May 11. Review.

10.

Risperidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review.

11.

Clozapine versus other atypical antipsychotics for schizophrenia.

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006633. doi: 10.1002/14651858.CD006633.pub2. Review.

12.

Clozapine: a distinct, poorly understood and under-used molecule.

Joober R, Boksa P.

J Psychiatry Neurosci. 2010 May;35(3):147-9. No abstract available.

13.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

14.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT).

Schizophr Bull. 2010 Jan;36(1):71-93. doi: 10.1093/schbul/sbp116. Epub 2009 Dec 2. Review.

15.

Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone.

Kelly DL, Wehring HJ, Linthicum J, Feldman S, McMahon RP, Love RC, Wagner T, Shim JC, Fowler DR.

Schizophr Res. 2009 Feb;107(2-3):134-8. doi: 10.1016/j.schres.2008.10.020. Epub 2008 Nov 22.

16.

Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects.

Gallitano-Mendel A, Wozniak DF, Pehek EA, Milbrandt J.

Neuropsychopharmacology. 2008 May;33(6):1266-75. Epub 2007 Jul 18.

17.

Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder.

Hoptman MJ, Volavka J, Czobor P, Gerig G, Chakos M, Blocher J, Citrome LL, Sheitman B, Lindenmayer JP, Lieberman JA, Bilder RM.

J Neuropsychiatry Clin Neurosci. 2006 Fall;18(4):509-15.

18.

Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.

Hoptman MJ, Volavka J, Weiss EM, Czobor P, Szeszko PR, Gerig G, Chakos M, Blocher J, Citrome LL, Lindenmayer JP, Sheitman B, Lieberman JA, Bilder RM.

Psychiatry Res. 2005 Nov 30;140(2):133-45. Epub 2005 Oct 25.

19.

The schizophrenia phenotype in 22q11 deletion syndrome.

Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R.

Am J Psychiatry. 2003 Sep;160(9):1580-6.

Supplemental Content

Support Center